8/29/2024
Patient Case Story: CC
Short Excerpt: Diagnosed with stage IV pancreatic cancer in 2019, CC underwent chemotherapy, radiation, and Whipple surgery, followed by metabolic therapies, a Mediterranean diet, and rigorous exercise. Now more than four years post-diagnosis, she remains active and cancer-free, a powerful example of resilience and the potential of comprehensive, integrative cancer care.
Patient Profile
- Age: 73 years old
- Gender: Female
- Diagnosis: Pancreatic Cancer
- Date of Diagnosis: May 2019
Initial Presentation
Primary Signs/Symptoms:
Digestive issues. The diagnosis followed the incidental discovery of the cancer during a routine annual scan. CC had a history of breast cancer diagnosed in 2015 but was considered to be in remission at the time of her pancreatic cancer diagnosis.CC also has a strong family history of pancreatic cancer.
Initial Treatment
CC’s initial treatment regimen was comprehensive and aggressive, consisting of:
- FOLFIRINOX Chemotherapy: A regimen combining leucovorin, fluorouracil, irinotecan, and oxaliplatin, administered over 12 sessions.
- Radiation Therapy: MRI-guided SBRT provided for one month to target local tumor control.
- Whipple Surgery: Performed in January 2020. Pathology showed a ypT2N1 pancreatic adenocarcinoma. 1 of 6 lymph nodes were positive. Post surgical scans have shown subcentimeter liver lesions which could indicate metastasis.
- Adjuvant Hyperbaric Oxygen Therapy: Aimed at improving oxygen delivery to hypoxic tumor areas and enhancing the efficacy of concurrent therapies.
Ongoing Therapies
Since August 2021, CC’s ongoing treatment has included:
- Repurposed Metabolically-Acting Medications: Metformin, Doxycycline, Atorvastatin, and Mebendazole.
- Dietary Modifications: A Mediterranean-style diet rich in proteins, vegetables, and fruits while low in sugar.
- Exercise Regimen: Engages in strenuous physical activity averaging over 5 one-hour sessions per week.
Current Status
As of August 2024, CC is 73 years old and has survived over 4 years from her initial stage 4 pancreatic cancer diagnosis. Her current BMI is 18.65, and her weight is 100 lbs. Despite her advanced stage at diagnosis, CC remains active and serves as a source of inspiration for other cancer patients.
Discussion
Survival Rates and Statistics
Stage 4 pancreatic cancer, characterized by distant metastasis, traditionally has a poor prognosis. According to population-based studies, the 1-year survival rate for patients with metastatic pancreatic cancer is approximately 10%, and the 3-year survival rate is around 1%. Median overall survival for this stage is typically between 2 to 6 months. The 5-year survival rate for stage 4 pancreatic cancer is notably low, around 1-3%.
Factors Contributing to Long-Term Survival
- Aggressive Initial Therapy: The FOLFIRINOX regimen has been shown to offer a survival advantage compared to gemcitabine-based therapies. Clinical trials have demonstrated improved overall survival with FOLFIRINOX compared to older treatment regimens.
- Repurposed Medications: Metformin, often used for diabetes, has shown potential anti-cancer effects in preclinical studies, potentially influencing pancreatic cancer biology. Doxycycline, atorvastatin, and mebendazole have also been investigated for their effects on cancer, though their clinical efficacy in pancreatic cancer remains under study.
- Lifestyle Modifications: A Mediterranean-style diet and regular exercise have been associated with better outcomes and improved quality of life in cancer patients. These modifications can impact systemic inflammation, metabolic health, and overall well-being.
- Possible Favorable Tumor Biology: Some patients may possess unique genetic or molecular characteristics that render them more responsive to treatment or slower to progress.
Psychosocial Impact
CC’s advice to other cancer patients is “Don’t Lose Hope.” Research suggests that maintaining a positive outlook and psychosocial support can positively influence cancer outcomes. While it is challenging to quantify the exact impact of mental attitude on survival, the supportive role of a positive mindset and hopefulness is recognized in improving patient quality of life and potentially influencing treatment response.
Conclusion
CC’s case is a notable example of extended survival in the context of stage 4 pancreatic cancer exceeding typical prognosis expectations. Her successful outcome is attributed to a combination of aggressive multimodal treatment, innovative repurposed therapies, rigorous lifestyle changes, and possibly favorable biological factors. This case underscores the importance of personalized, comprehensive treatment approaches and highlights the potential for improved outcomes even in advanced cancer stages.
Further research is warranted to understand better the factors contributing to exceptional survival and to refine treatment strategies for patients with metastatic pancreatic cancer.
References
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657314/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276299/
- https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/survival
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250924/
- https://www.ncbi.nlm.nih.gov/books/NBK518996/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295381/
- https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-023-00261-5
